Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

121. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial 28939629 2017 09 23 2017 09 23 1468-2060 2017 Sep 22 Annals of the rheumatic diseases Ann. Rheum. Dis. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. annrheumdis-2017-211781 10.1136/annrheumdis (...) -2017-211781 High adalimumab serum concentrations do not result in better response in patients with rheumatoid arthritis (RA), suggesting overexposure. We investigated whether patients with adalimumab concentrations >8 µg/mL can prolong their dosing interval by 50% without a clinically relevant change in disease activity. Consecutive patients with RA, treated with adalimumab 40 mg every other week for at least 28 weeks, were approached for this randomised, open-label, non-inferiority trial. Patients

EvidenceUpdates2017

122. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial 28859326 2017 09 01 2017 09 27 2017 09 27 1462-0332 56 9 2017 Sep 01 Rheumatology (Oxford, England) Rheumatology (Oxford) Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. 1586-1596 10.1093/rheumatology/kex223 To assess the efficacy and safety of initial COBRA-light vs COBRA (...) 9PHQ9Y1OLM Prednisolone YL5FZ2Y5U1 Methotrexate AIM IM Adult Aged Antirheumatic Agents administration & dosage adverse effects therapeutic use Arthritis, Rheumatoid diagnostic imaging drug therapy Comorbidity Disease Progression Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Humans Male Methotrexate administration & dosage adverse effects therapeutic use Middle Aged Prednisolone administration & dosage adverse effects therapeutic use Radiography Severity of Illness Index

EvidenceUpdates2017

123. [Tofacitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Tofacitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18 [Tofacitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V] Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18 [Tofacitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18. [Tofacitinib (rheumatoid arthritis) - benefit assessment

Health Technology Assessment (HTA) Database.2017

124. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis 28936808 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis. 405-417 10.1007/s40744-017-0081-3 Tocilizumab (TCZ) monotherapy has been proven as an effective treatment for rheumatoid arthritis (RA) in clinical trials (...) ):1797-808 10513792 Ann Rheum Dis. 2007 Nov;66(11):1473-8 17426065 J Rheumatol. 2009 Nov;36(11):2435-42 19833759 J Rheumatol. 2007 Feb;34(2):280-9 17304654 Perspect Clin Res. 2011 Oct;2(4):137-44 22145124 Biological therapy Monotherapy Patient-reported outcome measures Rheumatoid arthritis Tocilizumab 2017 05 02 2017 9 25 6 0 2017 9 25 6 1 2017 9 23 6 0 ppublish 28936808 10.1007/s40744-017-0081-3 10.1007/s40744-017-0081-3 PMC5696293

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

125. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment 28900875 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. 391-404 10.1007/s40744-017-0079-x To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA (...) Canada Inc., Mississauga, ON, Canada. Poulin-Costello Melanie M Amgen Canada Inc., Mississauga, ON, Canada. Isaila Maya M Amgen Canada Inc., Mississauga, ON, Canada. Collier David D Amgen Inc., Thousand Oaks, CA, USA. eng ClinicalTrials.gov NCT01927757 Journal Article 2017 09 12 England Rheumatol Ther 101674543 2198-6576 Adalimumab Antibodies Antirheumatic agents Etanercept Humanized Monoclonal Receptors Rheumatoid arthritis Tumor necrosis factor 2017 06 21 2017 9 14 6 0 2017 9 14 6 1 2017 9 14 6 0

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

127. Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis

Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis 28823986 2017 08 21 2017 08 21 1468-2060 2017 Aug 20 Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis. annrheumdis-2017-211608 10.1136/annrheumdis-2017-211608 Patients with rheumatoid arthritis (RA) are at increased risk of acute coronary syndrome (ACS) and suffer from poorer (...) syndrome epidemiology outcome rheumatoid arthritis secondary prevention Competing interests: AM and MH have nothing to declare. TJ reports personal fees from Astra Zeneca, personal fees from MSD, personal fees from Aspen, outside the submitted work. SWJ reports a fee for short talk at conference for Swedish cardiologists and general practitioners January 2016, arranged by Merck, Sharp & Dome. JA and Karolinska Institutet had research agreements with Abbvie, BMS, MSD, Pfizer, Roche, Astra-Zeneca, Lilly

EvidenceUpdates2017

128. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study 28855173 2017 08 31 2017 08 31 1468-2060 2017 Aug 30 Annals of the rheumatic diseases Ann. Rheum. Dis. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. annrheumdis-2017-211328 10.1136/annrheumdis-2017-211328 Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine (...) GlaxoSmithKline Research and Development, Stevenage, Hertfordshire, UK. eng Journal Article 2017 08 30 England Ann Rheum Dis 0372355 0003-4967 DMARDs (biologic) DMARDs (synthetic) cytokines rheumatoid arthritis treatment Competing interests: TT: grant/research support from Astellas Pharma, Bristol-Myers K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

129. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study 28798049 2017 08 11 2017 09 06 1468-2060 2017 Aug 10 Annals of the rheumatic diseases Ann. Rheum. Dis. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. annrheumdis-2017-211259 10.1136/annrheumdis-2017-211259 To assess the effect (...) of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

130. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial

Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial 28724365 2017 07 20 2017 08 17 1471-2474 18 1 2017 Jul 19 BMC musculoskeletal disorders BMC Musculoskelet Disord Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from (...) a randomized double blind controlled clinical trial. 310 10.1186/s12891-017-1673-3 The standard dose of rituximab used in rheumatoid arthritis (RA) is 1000 mg but recent studies have shown that low dose (500 mg) is also effective. Efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic Disease Modifying Anti Rheumatic Drugs (DMARDs), compared to leflunomide is unknown. In a tertiary care referral setting, we conducted a randomized, double blind controlled clinical

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

131. [Baricitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Baricitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V] Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14. [Baricitinib (rheumatoid arthritis) - benefit assessment

Health Technology Assessment (HTA) Database.2017

132. Risk of Obstructive Sleep Apnea and Its Association with Cardiovascular and Noncardiac Vascular Risk in Patients with Rheumatoid Arthritis: A Population-based Study

Risk of Obstructive Sleep Apnea and Its Association with Cardiovascular and Noncardiac Vascular Risk in Patients with Rheumatoid Arthritis: A Population-based Study 28765254 2017 08 02 2017 09 14 0315-162X 2017 Aug 01 The Journal of rheumatology J. Rheumatol. Risk of Obstructive Sleep Apnea and Its Association with Cardiovascular and Noncardiac Vascular Risk in Patients with Rheumatoid Arthritis: A Population-based Study. jrheum.170460 10.3899/jrheum.170460 To define the incidence (...) of obstructive sleep apnea (OSA) in patients with rheumatoid arthritis (RA) and determine whether OSA diagnosis predicts future cardiovascular disease (CVD) and noncardiac vascular events. Medical information pertaining to RA, OSA, CVD, and vascular diagnoses was extracted from a comprehensive medical record system for a geographically defined population of 813 patients previously diagnosed with RA and 813 age- and sex-matched comparator subjects. The risk for OSA in persons with RA versus comparators

EvidenceUpdates2017

133. Rheumatoid arthritis - musculoskeletal ultrasound

Rheumatoid arthritis - musculoskeletal ultrasound Rheumatoid arthritis - musculoskeletal ultrasound: Advice Statement 006-17 Search the full site Search keywords Our on-going projects: Advice Statement 006-17 Advice Statement 006-17 Contact the SHTG team Contact Healthcare Improvement Scotland with any SHTG questions: Email: Lead Health Services Researcher Lead for SHTG SHTG Project Officer Advice Statement 006/17 In patients with suspected rheumatoid arthritis, does the addition (...) of musculoskeletal ultrasound increase the ability of rheumatologists to confirm or rule out a diagnosis of rheumatoid arthritis at an earlier stage compared to conventional diagnostic assessment alone? Downloads Review This Advice Statement represents the view of the SHTG at the date of first publication. This Advice Statement will be considered for review 2 years post-publication, and at 2-yearly intervals thereafter. Published Date: 22 September 2017 Related pages NHS Scotland

SHTG Advice Statements2017

134. Clinically stable rheumatoid arthritis - musculoskeletal ultrasound

Clinically stable rheumatoid arthritis - musculoskeletal ultrasound Clinically stable rheumatoid arthritis - musculoskeletal ultrasound: Advice Statement 007-17 Search the full site Search keywords Our on-going projects: Advice Statement 007-17 Advice Statement 007-17 Contact the SHTG team Contact Healthcare Improvement Scotland with any SHTG questions: Email: Lead Health Services Researcher Lead for SHTG SHTG Project Officer Advice Statement 007/17 In patients with clinically stable rheumatoid (...) arthritis (clinical remission), can musculoskeletal ultrasound in addition to clinical examination detect or rule out inflammation that predicts subsequent joint damage to inform tapering and stopping treatment? Downloads Review This Advice Statement represents the view of the SHTG at the date of first publication. This Advice Statement will be considered for review 2 years post-publication, and at 2-yearly intervals thereafter. Published Date: 21 September 2017 Related pages NHS Scotland

SHTG Advice Statements2017

135. Clinically stable rheumatoid arthritis - musculoskeletal ultrasound

Clinically stable rheumatoid arthritis - musculoskeletal ultrasound Clinically stable rheumatoid arthritis - musculoskeletal ultrasound: evidence note 70 Search the full site Search keywords Our on-going projects: Evidence note 70 Evidence note 70 Contact the SHTG team Contact Healthcare Improvement Scotland with any SHTG questions: Email: Lead Health Services Researcher Lead for SHTG SHTG Project Officer Evidence note 70 What is the clinical effectiveness, cost effectiveness and safety of home (...) and mobile health monitoring in addition to usual care compared with usual care for adults with diabetes (Type 1 and Type 2)? Downloads Key points Musculoskeletal ultrasound is an imaging technique that has potential to inform decisions on tapering or discontinuation of therapy in rheumatoid arthritis patients who are in clinical remission. Two systematic reviews of observational studies, with overlapping included studies, found that synovitis detected by musculoskeletal ultrasound predicted risk

Evidence Notes from Healthcare Improvement Scotland2017

136. Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry 28840531 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry. 375-389 10.1007/s40744-017-0077-z Current recommendations for the management of rheumatoid arthritis (RA) focus (...) . vishvas.garg@abbvie.com. eng Journal Article 2017 08 24 England Rheumatol Ther 101674543 2198-6576 Adalimumab Biologic Corrona Real-world Rheumatoid arthritis Treat-to-target 2017 06 14 2017 8 26 6 0 2017 8 26 6 1 2017 8 26 6 0 ppublish 28840531 10.1007/s40744-017-0077-z 10.1007/s40744-017-0077-z PMC5696289 Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455 25264908 N Engl J Med. 2000 Nov 30;343 (22):1594-602 11096166 Autoimmun Rev. 2006 Jan;5(1):46-54 16338211 Arthritis Rheum. 2006 Jan;54(1):26-37

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

137. Treatment with Biologicals in Rheumatoid Arthritis: An Overview

Treatment with Biologicals in Rheumatoid Arthritis: An Overview 28831712 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Treatment with Biologicals in Rheumatoid Arthritis: An Overview. 247-261 10.1007/s40744-017-0073-3 Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the development and approval of the first biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumor necrosis factor (TNF) α at the end of the last century (...) @kssg.ch. Mueller Ruediger B RB Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland. eng Journal Article Review 2017 08 22 England Rheumatol Ther 101674543 2198-6576 B cell depletion Biological DMARDs IL-6 receptor inhibition Janus kinase inhibitors Review Rheumatoid arthritis T cell co-stimulation blockade TNF inhibitors Targeted synthetic DMARDs Therapy 2017 05 22 2017 8 24 6 0 2017 8 24 6 1 2017 8 24 6 0 ppublish 28831712 10.1007/s40744-017-0073

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

138. Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry 28831751 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry. 489-502 10.1007/s40744-017-0078-y Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed (...) , Gaithersburg, MD, USA. Radius Health, Inc, Wayne, PA, USA. Saunders Katherine K Corrona LLC, Southborough, MA, USA. Grant Shannon S Axio LLC, Seattle, WA, USA. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Kremer Joel J Albany Medical College and the Center for Rheumatology, Albany, NY, USA. eng Journal Article 2017 08 22 England Rheumatol Ther 101674543 2198-6576 Anti-TNF DAS28 Disease activity Rheumatoid arthritis 2017 05 26 2017 8 24 6 0 2017 8 24 6 1 2017 8 24 6 0 ppublish 28831751 10.1007

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

139. Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study

Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study 28819927 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study. 363-374 10.1007/s40744-017-0075-1 Rheumatoid arthritis (RA) produces debilitating morning stiffness. Exogenous glucocorticoids can help (...) Practice, College of Pharmacy, University of Illinois-Chicago, Chicago, IL, USA. RHolt@horizonpharma.com. eng ClinicalTrials.gov NCT02287610 Journal Article 2017 08 17 England Rheumatol Ther 101674543 2198-6576 Circadian Glucocorticoids Morning stiffness Outcome assessment Prednisone Rheumatoid arthritis 2017 06 22 2017 8 19 6 0 2017 8 19 6 1 2017 8 19 6 0 ppublish 28819927 10.1007/s40744-017-0075-1 10.1007/s40744-017-0075-1 PMC5696287 Ann Rheum Dis. 2003 Jul;62(7):593-6 12810417 RMD Open. 2016 Mar

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

140. Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis

Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis 28815445 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis. 281-291 10.1007/s40744-017-0072-4 Patients with rheumatoid arthritis (RA) suffer from high rates of depression but depression often remains undiagnosed and untreated among RA patients. Because of its high prevalence and its profound (...) . Karpouzas George A GA Harbor-UCLA Medical Center, Torrance, CA, USA. eng Journal Article 2017 08 16 England Rheumatol Ther 101674543 2198-6576 Depression Mental health Rheumatology 2017 05 08 2017 8 18 6 0 2017 8 18 6 1 2017 8 18 6 0 ppublish 28815445 10.1007/s40744-017-0072-4 10.1007/s40744-017-0072-4 PMC5696284 J Psychosom Res. 2010 Feb;68(2):187-93 20105702 Best Pract Res Clin Rheumatol. 2007 Oct;21(5):885-906 17870034 J Psychosom Res. 2006 May;60(5):469-76 16650587 Arthritis Rheum. 2003 Apr 15;49(2

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro